Abbott has received CE Mark approval for Libre Duo, the world's first sensor that continuously monitors both glucose and ketone levels for people with diabetes. This device helps manage daily glucose and detects rising ketones that can lead to dangerous diabetic ketoacidosis, without needing blood or urine tests. It integrates with the Libre digital health system and supports automated insulin delivery systems. Abbott plans to launch Libre Duo in select European countries later this year, marking a significant advancement in diabetes management technology.
The American Cancer Society (ACS) updated its colorectal cancer screening guidelines, reaffirming Cologuard and Cologuard Plus as preferred noninvasive screening tests for adults aged 45 and older at average risk. These stool-based tests, used every ...
Abbott presented 11 new studies at ASCO 2026 demonstrating advances in cancer diagnostics that improve early detection, treatment guidance, and patient outcomes. Key data include enhanced sensitivity in early triple-negative breast cancer and low psy...
